Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MEOH | PRESS-RELEASE | bearish | 6/10 | Methanex will indefinitely idle its New Zealand production facilities starting Q1 2027, having sold substantially all of | Sep 1, 2026 |
| RARE | PRESS-RELEASE | bullish | 7/10 | Ultragenyx announced publication of 96-week Phase 3 data for GENGLYCOS (DTX401) gene therapy in glycogen storage disease | Sep 1, 2026 |
| BMRN | PRESS-RELEASE | neutral | 4/10 | BioMarin completed its acquisition of Alesta Therapeutics, adding ALE1, a Phase 1/2a oral small-molecule candidate for h | Sep 1, 2026 |
| BMRA | PRESS-RELEASE | mixed | 6/10 | Biomerica reported fiscal 2026 Q4 net sales of ~$875K (+17% YoY) and a net loss improvement to ~$1.1M, while full-year r | Sep 1, 2026 |
| PMN | PRESS-RELEASE | neutral | 3/10 | ProMIS Neurosciences announced its participation in five investor conferences in September 2026, including a fireside ch | Sep 1, 2026 |
| OCGN | PRESS-RELEASE | bullish | 7/10 | Ocugen dosed the first patient in the global Phase 3 ArMaDa3 trial of OCU410 for geographic atrophy (GA) and highlighted | Sep 1, 2026 |
| PMVP | PRESS-RELEASE | bearish | 8/10 | PMV Pharmaceuticals priced a dilutive underwritten public offering of 22,055,000 common shares plus pre-funded warrants | Aug 31, 2026 |
| KZIA | PRESS-RELEASE | bearish | 6/10 | Kazia Therapeutics closed an oversubscribed, tranched public offering generating approximately $40 million in upfront gr | Aug 31, 2026 |
| PMVP | PRESS-RELEASE | bearish | 6/10 | PMV Pharma commences an underwritten public offering of common stock, pre-funded warrants, and warrants. The offering si | Aug 31, 2026 |
| PMVP | PRESS-RELEASE | bullish | 8/10 | PMV Pharma announced updated interim Phase 2 data for rezatapopt in TP53 Y220C-mutant platinum-resistant/refractory ovar | Aug 31, 2026 |
| CYTK | PRESS-RELEASE | bullish | 7/10 | Cytokinetics presented positive additional Phase 3 results at ESC 2026 showing aficamten (MYQORZO) improves cardiac stru | Aug 29, 2026 |
| TENX | PRESS-RELEASE | mixed | 7/10 | Tenax Therapeutics presented additional Phase 3 LEVEL trial data for TNX-103 (oral levosimendan) in PH-HFpEF at ESC 2026 | Aug 29, 2026 |
| CRSP | PRESS-RELEASE | bullish | 7/10 | CRISPR Therapeutics presented one-year durability data from its Phase 1a trial of CTX310, an in vivo CRISPR/Cas9 gene ed | Aug 28, 2026 |
| VVOS | PRESS-RELEASE | neutral | 4/10 | Vivos Therapeutics announced definitive agreements with South Palm Cardiovascular Associates to form AIM Florida, a phys | Aug 28, 2026 |
| AMRN | PRESS-RELEASE | neutral | 4/10 | Amarin announced a post-hoc analysis from the REDUCE-IT trial at ESC 2026, showing that highly adherent patients on icos | Aug 28, 2026 |
| BLRX | PRESS-RELEASE | bearish | 6/10 | BioLineRx announced a $3.75M registered direct offering and concurrent private placement, selling 1,348,921 ADSs at $2.7 | Aug 28, 2026 |
| IBIO | PRESS-RELEASE | neutral | 4/10 | iBio reported fiscal year 2026 results with revenue of $0.1M (down from $0.4M) and a net loss of -$33.0M, wider than the | Aug 28, 2026 |
| TEVA | PRESS-RELEASE | bullish | 6/10 | Teva announced a stalking-horse bid to acquire BioXcel Therapeutics' IGALMI (dexmedetomidine sublingual film) and relate | Aug 28, 2026 |
| QNRX | PRESS-RELEASE | bearish | 7/10 | Quoin Pharmaceuticals announced a private placement raising up to ~$50M in gross proceeds, with ~$30.8M upfront from iss | Aug 28, 2026 |
| BTAI | PRESS-RELEASE | bearish | 9/10 | BioXcel Therapeutics announced it has entered into a stalking horse asset sale agreement with Teva Pharmaceuticals for s | Aug 28, 2026 |
| IMRN | PRESS-RELEASE | neutral | 4/10 | Immuron reported FY26 results with record sales of A$7.7M (+6% YoY) and net profit improvement of A$1.4M. The company hi | Aug 28, 2026 |
| QNRX | PRESS-RELEASE | bullish | 7/10 | Quoin Pharmaceuticals announced positive interim Phase 2/3 results for QRX003 in Netherton Syndrome: 4 of 6 patients (66 | Aug 28, 2026 |
| LFVN | PRESS-RELEASE | bearish | 7/10 | LifeVantage reported Q4 FY2026 revenue of $42.4M (down 23.1% YoY) and GAAP EPS of $0.10 (down from $0.15 YoY), missing c | Aug 27, 2026 |
| ROIV | PRESS-RELEASE | bullish | 8/10 | Priovant Therapeutics, a Roivant (ROIV) company, announced FDA approval of LISRAYA (brepocitinib) for adult dermatomyosi | Aug 27, 2026 |
| ROIV | PRESS-RELEASE | bullish | 8/10 | FDA approved LISRAYA (brepocitinib) for adult dermatomyositis, the first targeted therapy for this indication. Approval | Aug 27, 2026 |
| GRML | PRESS-RELEASE | mixed | 6/10 | Greenland Mines announced it expects to complete the acquisition of Neo North Star Resources (Sarfartoq Nd-Pr rare earth | Aug 27, 2026 |
| ENTX | PRESS-RELEASE | neutral | 2/10 | Entera Bio announced that CEO Miranda Toledano will present at three upcoming investor conferences (Cantor, Guggenheim, | Aug 27, 2026 |
| BHC | PRESS-RELEASE | neutral | 1/10 | Bausch Health announced the recipients of its 2026 Aspire Higher Scholarship Program, awarding six students up to $10,00 | Aug 27, 2026 |
| MBX | PRESS-RELEASE | bullish | 8/10 | MBX Biosciences announced the first patient dosed in its pivotal Phase 3 oPTimize trial for once-weekly canvuparatide in | Aug 27, 2026 |
| CUVL | PRESS-RELEASE | mixed | 5/10 | Clinuvel Pharmaceuticals reported FY2026 annual results with revenue of $94.0M (down 1% YoY) and net profit after tax of | Aug 27, 2026 |